N00001 |
 |
EGF | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N00276 |
 |
EGF* | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00229 |
 |
TGFA | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00230 |
 |
TGFA* | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00277 |
 |
EREG | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00278 |
 |
EREG* | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00279 |
 |
AREG | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00280 |
 |
AREG* | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N01354 |
 |
BPA | → | EGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N10005 |
 |
| | (Gefitinib,Erlotinib,Afatinib,Dacomitinib) ⊥ | |
N10006 |
 |
| | Osimertinib ⊥ | |
N00014 |
 |
| | EGFR* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N00513 |
 |
| | EGFR* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N00006 |
 |
| | EGFR* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00041 |
 |
| | EGFR* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00021 |
 |
EGF | → | (ERBB2+EGFR) | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N10009 |
 |
| | (Trastuzumab,Trastuzumab_emtansine,Pertuzumab,Lapatinib,Neratinib,Tucatinib,Margetuximab) ⊥ | |
N00022 |
 |
EGF | → | (ERBB2*+EGFR) | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N10009 |
 |
| | (Trastuzumab,Trastuzumab_emtansine,Pertuzumab,Lapatinib,Neratinib,Tucatinib,Margetuximab) ⊥ | |
N00252 |
 |
EGF | → | (ERBB2*+EGFR) | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00015 |
 |
PDGF | → | PDGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00016 |
 |
PDGF* | → | PDGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00018 |
 |
| | PDGFR* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00215 |
 |
KITLG | → | KIT | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00003 |
 |
| | KIT* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00019 |
 |
FGF | → | FGFR | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00020 |
 |
| | FGFR* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00011 |
 |
| | FGFR3* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | MSK1 | → | MYC |
N00217 |
 |
FLT3LG | → | FLT3 | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00004 |
 |
| | FLT3* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00233 |
 |
IGF | → | IGF1R | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00235 |
 |
IGF2* | → | IGF1R | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00237 |
 |
IGF2 | → | IGF1R* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00216 |
 |
HGF | → | MET | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00246 |
 |
HGF* | → | MET | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00005 |
 |
| | MET* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N00259 |
 |
| | MET* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00248 |
 |
| | MET* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N10024 |
 |
| | (Capmatinib,Tepotinib) ⊥ | |
N01062 |
 |
| | MET* | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N10001 |
 |
| | Imatinib ⊥ | |
N10002 |
 |
| | (Dasatinib,Nilotinib,Bostinib,Ponatinib,Asciminib) ⊥ | |
N00002 |
 |
| | BCR-ABL | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK |
N00274 |
 |
| | NS5A | ⊣ | GRB2 |
N01408 |
 |
| | | | Metals | → | ROS | → | RAS | → | RAF | → | MEK | → | ERK | → | AP1 |
N00009 |
 |
| | | | | | TRK* | → | RAS | → | RAF | → | MEK | → | ERK |
N01064 |
 |
| | | | | | RET* | → | RAS | → | RAF | → | MEK | → | ERK |
N10025 |
 |
| | | | | | Selpercatinib,Pralsetinib ⊥ | |
N00008 |
 |
| | | | | | RET* | → | RAS | → | RAF | → | MEK | → | ERK |
N10003 |
 |
| | | | | | Crizotinib ⊥ | |
N10004 |
 |
| | | | | | (Alectinib,Ceritinib,Brigatinib,Lorlatinib) ⊥ | |
N00007 |
 |
| | | | | | EML4-ALK | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N00160 |
 |
| | | | | | K1 | → | RAS |
N00077 |
 |
| | | | | | | | HRAS* | → | RAF | → | MEK | → | ERK | → | MSK1 | → | MYC |
N00078 |
 |
| | | | | | | | HRAS* | → | RAF | → | MEK | → | ERK | → | MSK1 | → | MYC |
N00012 |
 |
| | | | | | | | (KRAS*,NRAS*) | → | RAF | → | MEK | → | ERK | → | CCND1 |
N10007 |
 |
| | | | | | | | | | (Vemurafenib,Dabrafenib,Encorafenib) ⊥ | |
N10008 |
 |
| | | | | | | | | | | | (Trametinib,Cobimetinib,Binimetinib) ⊥ | |
N00013 |
 |
| | | | | | | | | | BRAF* | → | MEK | → | ERK |
| | |
N01360 |
 |
P4 | → | (PGR+SRC) | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N01361 |
 |
(P4,MPA) | → | (PGR+SRC) | → | GRB2 | → | SOS | → | RAS | → | RAF | → | MEK | → | ERK | → | CCND1 |
N01351 |
 |
| | E2 | → | ESR1/2 | → | SRC | → | RAS | → | RAF | → | MEK | → | ERK | → | CREB |
N01353 |
 |
| | E2 | → | ESR1/2 | → | SRC | → | RAS | → | RAF | → | MEK | → | ERK | → | (ESR1/2,AP1) | ⇒ | CHRNA9 |
N01352 |
 |
| | BPA | → | ESR1/2 | → | SRC | → | RAS | → | RAF | → | MEK | → | ERK |
| | |
N01343 |
 |
| | ACh | → | CHRNA7 | → | Ca2+ | → | RAS | → | RAF | → | MEK | → | ERK | → | CREB |
N01344 |
 |
| | (NNK,NNN) | → | CHRN | → | Ca2+ | → | RAS | → | RAF | → | MEK | → | ERK | → | (FOS,JUN,MYC,BCL2) |
|